ILEX Oncology & LeukoSite report results from pivotal Phase II CAMPATH (R) trial; Results suggest new hope for refractory chronic lymphocytic leukemia

der to reduce the incidence and severity of infusion-related adverse events. Patients also received prophylactic anti-infective treatment to reduce the risk of opportunistic infections. The primary endpoint for this trial was overall response rate (complete and partial response), and the study objective was to demonstrate a major response rate of at least 20 percent. Response rate was assessed by an independent review panel in accordance with the National Cancer Institute's guidelines for the diagnosis and treatment of CLL.

Of 93 evaluable patients, 31 demonstrated an objective response to treatment, for an overall response rate of 33%. Two of these responses were complete (2%) and 29 were partial responses (31%). Another 55 (59%) patients had disease stabilization. Median survival time has not yet been reached at about 10 months after the last patient was enrolled.

The safety profile of CAMPATH was consistent with that seen in previous studies and was judged by the investigators to be acceptable in this group of endstage CLL patients.

Adverse effects associated with CAMPATH in this study of 93 patients were mostly mild to moderate infusion-related symptoms. Severe (grade 3 and 4) infusion-related symptoms included: fever (13%), rigors (11%), dyspnea (6%), and hypotension (1%). During the study patients developed severe (grade 3 and 4) thrombocytopenia (low platelet count, 51%) or neutropenia (low white blood cell count, 61%) that usually improved within two months post-therapy. Some patients entering the study with severe (grade 3 and 4) thrombocytopenia and neutropenia improved to grade 2 or better within two months post-therapy: thrombocytopenia -- 7 of 19 (37%) patients improved,neutropenia -- 11 of 17 (65%) patients improved.

No unexpected serious adverse events were reported. The incidence of serious infections was reported to be 20% on this trial. It should be noted that infection is a common complication and cause of death

Contact: Deborah Sibley, ILEX Oncology
Porter Novelli

Page: 1 2 3 4 5

Related medicine news :

1. The 23rd Congress of the European Society for Therapeutic Radiology and Oncology (ESTRO)
2. Oncology Nursing Society honors Fox Chase Cancer Center nurse with Radiation Therapy Nursing Award
3. The Lancet Oncology (TLO)
4. The Lancet Oncology press release
5. The Lancet Oncology (TLO) and the Lancet Infectious Diseases (TLID)
6. The Lancet Oncology (TLO) June 2002
7. The Lancet Oncology (TLO) and The Lancet Infectious Diseases (TLID)
8. The Lancet Oncology and The Lancet Infectious Diseases
9. V. Craig Jordan Will Present Results Of Raloxifene Breast Cancer Study At American Society For Clinical Oncology Meeting
10. First UK cases of previously rare disease reported in gay men
11. Health care report cards may increase racial/ethnic disparities in bypass operations

Post Your Comments:
(Date:10/9/2015)... ... 09, 2015 , ... Smoke alarms can save lives. In fact, according to ... dying in reported home fires in half. As part of Fire Prevention Week, ... installed and maintained. , Half of home fire deaths result from fires reported between ...
(Date:10/9/2015)... (PRWEB) , ... October 09, 2015 , ... ... offering a special promotion on Invisalign, the orthodontic system that uses clear, plastic ... aligners are almost invisible against the teeth, which allow patients to complete treatment ...
(Date:10/9/2015)... ... October 09, 2015 , ... Matrix IT Medical Tracking ... for TRACTUS, the world’s first sterile field scanner. , The TRACTUS ... the FDA’s recent Unique Device Identifier (UDI) Final Rule, which will require manufacturers ...
(Date:10/9/2015)... ... October 09, 2015 , ... The Asthma and Allergy Foundation of ... Disease Control and Prevention (CDC) to improve the knowledge and skills of underserved adults ... awarded a project by the CDC and allows AAFA to continue vital efforts to ...
(Date:10/9/2015)... ... October 09, 2015 , ... Cambias Insurance ... surrounding communities, is initiating a combined charity effort with Animal Rescue New Orleans ... southern Louisiana. , Animal Rescue New Orleans is a non-profit organization committed ...
Breaking Medicine News(10 mins):
(Date:10/8/2015)...  Trovagene, Inc., (NASDAQ:   TROV) a developer ... of results from a field experience analysis featuring ... (PCM) platform to accurately identify mutational status, ... appropriate therapy for patients. Mark Erlander , ... the results today in an oral presentation titled ...
(Date:10/8/2015)... 2015 " Biomedical Refrigerators and ... and Forecast 2014 - 2022 " , the biomedical ... in 2013 and is anticipated to expand at a CAGR ... billion in 2022. --> " Biomedical Refrigerators ... Trends and Forecast 2014 - 2022 " , the ...
(Date:10/8/2015)... 2015 http://www.researchandmarkets.com/research/pvzb7x/natural_language ... "Natural Language Processing Market for Health ... (Rule-Based, Statistical, & Hybrid NLP Solutions), Region ... Africa, Latin America) - Global Forecast to ... --> http://www.researchandmarkets.com/research/pvzb7x/natural_language ) has announced the ...
Breaking Medicine Technology:
Cached News: